COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL

被引：0
|
作者：
Sasse, Andre [1 ]
Carvalho, Adriana [1 ]
机构：
[1] Univ Estadual Campinas, UNICAMP, Ctr Evidence Oncol, CEVON, Campinas, SP, Brazil
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN
    Moreno, V
    Martinez-Amores, B.
    Barriuso, J.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    VALUE IN HEALTH, 2012, 15 (07) : A421 - A422
  • [2] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain
    Moreno, Victor
    Martinez-Amores, Brezo
    Barriuso, Jorge
    Mezquita, Laura
    Ibanez de Caceres, Inmaculada
    Ayuso Sacido, Angel
    Maria Pena, Jose
    Perona, Rosario
    Belda-Iniesta, Cristobal
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] COST-EFFECTIVENESS OF CETUXIMAB VERSUS PANITUMUMAB IN THIRD-LINE THERAPY FOR CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER IN BRAZIL
    Sasse, Andre
    Carvalho, Adriana
    ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
  • [4] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [5] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [6] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [7] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [8] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer
    Ruiz-Millo, Oreto
    Albert-Mari, Asuncion
    Sendra-Garcia, Ana
    Victor Jimenez-Torres, N.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (05) : 341 - 350
  • [10] COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER
    Tikhonova, I
    Hoyle, M.
    Snowsill, T.
    Crathorne, L.
    Varley-Campbell, J.
    Peters, J.
    Briscoe, S.
    Bond, M.
    Huxley, N.
    VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
12345